Genocea presents GEN-009 data at ASCO
Genocea announced clinical results from its ongoing Phase 1/2a trial for GEN-009, the company's neoantigen vaccine candidate. The results were presented in a poster over the weekend at this year's American Society of Clinical Oncology, or ASCO. In the five patients for whom immune response results are available to date, GEN-009 monotherapy elicited T cell responses to 91% of the vaccine neoantigens administered. GEN-009 has proven to be unique among neoantigen vaccines in its ability to elicit ex vivo CD8+ T cell responses, which were observed for 47% of vaccine neoantigens. Inclusive of the results seen after in vitro stimulation, the CD8+ T cell response frequency was 53%. GEN-009 has been well tolerated to date, with no dose-limiting toxicities.